Glp-1 receptor agonists naion lawsuit claims are growing rapidly across the United States. Thousands of patients took popular weight-loss and diabetes drugs like Ozempic and Mounjaro. Some of those patients developed a serious eye condition called NAION. This condition causes sudden, permanent vision loss with no known cure.
- What Is the Glp-1 Receptor Agonists Naion Lawsuit About?
- MDL Case Status and Key Facts
- Who Qualifies for the Glp-1 Receptor Agonists Naion Lawsuit?
- How to File a Glp-1 Receptor Agonists Naion Lawsuit Claim
- Settlement Updates and What to Expect
- State-by-State Considerations
- Frequently Asked Questions
As a result, a dedicated federal multidistrict litigation now consolidates these claims. Plaintiffs allege that drug manufacturers Novo Nordisk and Eli Lilly failed to warn about this devastating risk. If you used a GLP-1 medication and experienced vision loss, you may qualify to seek compensation.
Case Timeline
Last checked: May 23, 2026
What Is the Glp-1 Receptor Agonists Naion Lawsuit About?
| MDL Detail | Current Data |
|---|---|
| MDL Number | MDL-3163 |
| Pending Cases | 1 |
| Presiding Judge | TBD |
| Federal District | TBD |
| Data Source | U.S. Judicial Panel on Multidistrict Litigation |
| Last Updated | June 01, 2026 |
The glp-1 receptor agonists naion lawsuit centers on a class of diabetes and weight-loss medications. These drugs include Ozempic, Wegovy, and Rybelsus made by Novo Nordisk. They also include Mounjaro, Zepbound, and Trulicity made by Eli Lilly. GLP-1 receptor agonists work by mimicking a gut hormone that regulates blood sugar and appetite. Millions of Americans began using these medications in recent years. However, a growing body of evidence links them to a serious eye condition.
NAION stands for Non-Arteritic Anterior Ischemic Optic Neuropathy. It occurs when blood flow to the optic nerve is suddenly cut off. The optic nerve tissue dies from lack of oxygen. Patients typically wake up with painless but severe vision loss in one eye. In most cases, the damage is permanent and irreversible. There is currently no proven medical or surgical treatment that restores lost vision from NAION.
The glp-1 receptor agonists naion lawsuit alleges that manufacturers knew or should have known about this risk. A landmark July 2024 study published in JAMA Ophthalmology found alarming results. Diabetic patients using semaglutide faced more than four times the risk of developing NAION. Overweight patients using the drug faced more than seven times the risk.
Despite this evidence, U.S. drug labels still carry no NAION warning. The European Medicines Agency added NAION as a side effect to European labels in June 2025. Plaintiffs argue the manufacturers’ failure to warn caused preventable harm.
MDL Case Status and Key Facts
| Detail | Information |
|---|---|
| MDL Number | 3163 |
| Full Name | In Re: GLP-1 Receptor Agonists (GLP-1 RAs) NAION Products Liability Litigation |
| Presiding Judge | Judge Karen S. Marston |
| Federal District | Eastern District of Pennsylvania |
| Date Created | December 15, 2025 |
| Approximate Case Count | 86 and growing |
| Named Defendants | Novo Nordisk, Eli Lilly |
| Bellwether Trials | Not yet scheduled (estimated 2028 or later) |
| Next Major Event | Science Day — June 2, 2026 |
The Judicial Panel on Multidistrict Litigation created MDL-3163 on December 15, 2025. The panel determined that NAION vision loss claims involve distinct medical and scientific issues. These claims require different experts and causation analysis than the gastrointestinal injury cases in the related MDL-3094. As a result, the JPML created a separate MDL specifically for glp-1 receptor agonists naion lawsuit claims.
The litigation started with roughly 30 cases at inception. By April 2026, approximately 73 federal cases were pending. Nineteen new cases were added in April alone. In January 2026, Judge Marston established a direct filing process. New plaintiffs can now file directly into the MDL. A “Science Day” hearing is scheduled for June 2, 2026. Both sides will present scientific evidence about the GLP-1 and NAION connection. However, bellwether trials remain years away.
Who Qualifies for the Glp-1 Receptor Agonists Naion Lawsuit?
You might be eligible to file a glp-1 receptor agonists naion lawsuit if you meet certain criteria. First, you must have taken a GLP-1 receptor agonist medication. This includes Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda, or Victoza. Second, you must have received a confirmed NAION diagnosis from an ophthalmologist or neuro-ophthalmologist. The diagnosis should be supported by diagnostic testing such as visual field tests or optical coherence tomography.
Typically, there should be a clear timeline connecting your medication use and vision loss. For example, NAION onset during active GLP-1 use strengthens the claim. A dose increase shortly before symptoms appeared is also relevant. Even partial vision recovery does not disqualify you. Pain, suffering, medical expenses, and lost quality of life remain compensable injuries.
To build a strong case, you will need several types of evidence. Prescription records and pharmacy fill history prove GLP-1 use and duration. Ophthalmology records confirm the NAION diagnosis. Diagnostic test results document the extent of damage. You should also gather all treating physician notes about your vision symptoms. A licensed attorney experienced in pharmaceutical litigation can help you evaluate your specific situation and gather the right documentation.
How to File a Glp-1 Receptor Agonists Naion Lawsuit Claim
Filing a glp-1 receptor agonists naion lawsuit begins with consulting a qualified attorney. Most pharmaceutical injury lawyers offer free case evaluations. They work on contingency, meaning you pay nothing unless you recover compensation. Your attorney will review your medical records and prescription history. They will determine whether your case meets the criteria for inclusion in MDL-3163.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Once retained, your attorney will file a complaint in the Eastern District of Pennsylvania. Judge Marston’s direct filing order streamlines this process. You will then complete a Plaintiff Fact Sheet. This document provides essential details about your medication use, medical history, and injuries. Discovery will follow as the MDL progresses through its pretrial phases.
The statute of limitations is critical. In most states, you have two to four years to file a claim. However, the discovery rule may extend this deadline. The clock typically starts when you knew or should have known that your GLP-1 medication caused your vision loss. Since the JAMA study was published in July 2024, many plaintiffs argue their discovery date is recent. Regardless, you should not delay. Consult an attorney as soon as possible to protect your legal rights.
Settlement Updates and What to Expect
As of May 2026, no settlements have been announced in the glp-1 receptor agonists naion lawsuit. This is expected given the litigation’s early stage. The MDL was created only five months ago. Science Day has not yet occurred. Discovery is still in its earliest phases. Neither Novo Nordisk nor Eli Lilly has publicly indicated willingness to negotiate a global settlement.
For context, pharmaceutical MDLs typically follow a multi-year timeline. After Science Day, the court will address expert discovery and Daubert challenges. Bellwether trials — test cases that help both sides assess claim values — are estimated for 2028 or later. Settlement discussions usually intensify after bellwether verdicts reveal how juries respond to the evidence.
Several factors will affect individual case values in the glp-1 receptor agonists naion lawsuit. The severity of vision loss matters significantly. Bilateral NAION affecting both eyes typically commands higher compensation. The duration of GLP-1 use and strength of the causal timeline are also important. Additionally, the European label change adds weight to failure-to-warn arguments. Each case is unique, so you should discuss potential outcomes with your attorney.
State-by-State Considerations
State tort reform laws significantly affect glp-1 receptor agonists naion lawsuit claims. Each state has different rules for damage caps, statutes of limitations, and comparative fault. For example, New Jersey has the most significant state-level parallel litigation. Two separate Multicounty Litigations are pending in New Jersey Superior Court. Pennsylvania also has notable state-court filings. States with high GLP-1 prescription rates — including Texas, Florida, and California — likely have substantial plaintiff populations as well. You can learn more about how your state’s laws apply at our state-by-state tort reform guide.
Filing in state court versus federal court involves strategic considerations. Some plaintiffs pursue both paths simultaneously. State courts may offer different procedural advantages. However, the federal MDL provides an efficient consolidated process. Your attorney can advise on the best approach based on where you live and the specifics of your glp-1 receptor agonists naion lawsuit claim.
Frequently Asked Questions
What GLP-1 drugs are linked to NAION vision loss?
The drugs named in the litigation include Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda, and Victoza. Both semaglutide and tirzepatide products are under scrutiny. If you took any GLP-1 receptor agonist and developed vision problems, consult an attorney to evaluate your situation.
Is NAION vision loss permanent?
In most cases, yes. NAION causes irreversible damage to the optic nerve. The nerve tissue that dies from lack of blood flow does not regenerate. There is currently no proven treatment to restore vision lost to NAION. Some patients experience stabilization, but meaningful recovery is rare.
How long do I have to file a glp-1 receptor agonists naion lawsuit?
The statute of limitations varies by state, typically ranging from two to four years. The discovery rule may extend your deadline if you only recently learned that your medication caused your vision loss. However, deadlines can pass quickly. You should consult a licensed attorney as soon as possible to determine your specific filing window.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- U.S. Judicial Panel on Multidistrict Litigation (JPML)
- U.S. Department of Justice
- FDA Safety Alerts & Recalls
- Centers for Disease Control and Prevention
- U.S. Environmental Protection Agency
Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
- All Active MDL Cases
- More in This Category
- Tort Reform by State — 50-State Comparison
- All 50 State Tort Reform Guides
- Mass Tort Explainers
- Demographic Guides
- Mass Tort Tips
- North Carolina Tort Reform Guide
- New York Tort Reform Guide
- Pennsylvania Tort Reform Guide
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.